0000899243-20-021756.txt : 20200807 0000899243-20-021756.hdr.sgml : 20200807 20200807160912 ACCESSION NUMBER: 0000899243-20-021756 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200805 FILED AS OF DATE: 20200807 DATE AS OF CHANGE: 20200807 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fink Eric CENTRAL INDEX KEY: 0001784038 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 201085295 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 171 OYSTER POINT BLVD., SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-05 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001784038 Fink Eric C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Human Resources Officer Common Stock 2020-08-05 4 S 0 1504 69.3185 D 950 D Common Stock 2020-08-05 4 S 0 950 70.1008 D 0 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2020. Represents the weighted average sale price of the shares sold ranging from $68.855 to $69.75 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents the weighted average sale price of the shares sold ranging from $69.98 to $70.30 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/Tricia Suvari, as Attorney-in-Fact 2020-08-07